LR-90
(Synonyms: 2,2'-((((((亚甲基双(2-氯-4,1-亚苯基))二(氮烷二基))二(羰基))双(氮烷二) 目录号 : GC31437
LR-90是晚期糖基化终产物(advancedglycationendproduct(AGE))抑制剂，能够抑制人单核细胞的炎症反应。LR-90也可用于糖尿病动物模型研究。
Cas No.:245075-84-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes[1]. LR-90 is also used in the research of diabetic animal model[2].
LR-90 (0, 25, 50, 100, and 200 μM) inhibits RAGE, MCP-1, COX-2, IP-10 and NOX2 mRNA expression in THP-1 cells in a dose-dependent manner, after pretreatment 1 h befor S100b stimulatation for 4 hours[1].LR-90 (0, 25, 50, 100, and 200 μM) dose-dependently and significantly blocks THP-1 cells adherence to endothelial cells after pretreatment 1 h befor S100b stimulatation for 24 hours[1].LR-90 (0, 25, 50, 100, and 200 μM, for 24 hours) shows no effect on the cell viability of THP-1 cells[1].|| Cell Viability Assay[1]||Cell Line:|THP-1 cells|Concentration:|0, 25, 50, 100, and 200 μM|Incubation Time:|24 hours|Result:|Showed no cytotoxicity to THP-1 cells.|| RT-PCR[1]||Cell Line:|THP-1 cells|Concentration:|0, 25, 50, 100, and 200 μM|Incubation Time:|One hour before S100b addition for 4 hours|Result:|Dose-dependently inhibited mRNA expression of RAGE, MCP-1, COX-2, IP-10, and NOX2 stimulated with S100b.
LR-90 (50 mg/L, p.o. for 27 weeks) significantly reduces plasma lipids, modestly affects hyperglycaemia in ZDF rats[2].LR-90 (50 mg/L) decreases renal AGE, AGER and lipid peroxidation[2].|| Animal Model:|Male ZDF rats (13 to 40 weeks)[2]|Dosage:|50 mg/L|Administration:|P.O. for 27 weeks|Result:|Significantly reduced plasma triacylglycerol and cholesterol by ∼55% and ∼30%, respectively. Modestly affected hyperglycaemia and blood pressure. Lowered the body weight.
[1]. Figarola JL, et al. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes. 2007 Mar;56(3):647-55. [2]. Figarola JL, et al. LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia. 2008 May;51(5):882-91.
| Cas No. | 245075-84-7 | SDF | |
| 别名 | 2,2'-((((((亚甲基双(2-氯-4,1-亚苯基))二(氮烷二基))二(羰基))双(氮烷二 | ||
| Canonical SMILES | O=C(NC1=CC=C(C=C1)OC(C)(C)C(O)=O)NC(C(Cl)=C2)=CC=C2CC3=CC=C(C(Cl)=C3)NC(NC4=CC=C(C=C4)OC(C)(C)C(O)=O)=O | ||
| 分子式 | C35H34Cl2N4O8 | 分子量 | 709.57 |
| 溶解度 | DMSO : ≥ 100 mg/mL (140.93 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4093 mL | 7.0465 mL | 14.093 mL |
| 5 mM | 0.2819 mL | 1.4093 mL | 2.8186 mL |
| 10 mM | 0.1409 mL | 0.7047 mL | 1.4093 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet